Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

AstraZeneca

Status and phase: Suspended; Phase 2

Conditions: Carcinoma, Renal Cell; Kidney Neoplasms

Treatments: Drug: ZD6126; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00065572

D2820C00018

6126IL/00018

Details and patient eligibility

About

The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnosed metastatic renal cell carcinoma
• Suitable for nephrectomy

Exclusion criteria

• Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
• Significant cardiac event within 3 months of entry
• Any history of coronary angioplasty or history of myocardial infarction

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind